Francisco J. Esteva: Capivasertib combined with fulvestrant offers new hope in breast cancer
Francisco J. Esteva, Lenox Hill Hospital shared a post on LinkedIn:
“Capivasertib combined with fulvestrant marks a significant advancement for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer featuring PIK3CA, AKT1, or PTEN alterations.
This FDA approval was supported by the CAPItello-291 trial, which demonstrated a significant improvement in progression-free survival among the biomarker-positive population, offering new hope in breast cancer treatment. Being able to review the clinical trial protocol on the J CLIN ONCOL paper is helpful.
More studies are needed to determine the optimal sequencing of therapy in patients with ER/PR+, HER2- metastatic breast cancer with alterations in the Akt/PIK3CA pathway.”
Source: Francisco J. Esteva/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023